Privo Technologies Reports High Success Rate in Oral Cancer Trial
1 report, 1 independent
Updated Wed 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Privo Technologies issued a clinical update regarding the CLN-004 Phase 2 trial of PRV111, a nanoengineered patch for oral cancer treatment. The company reported that 95.5% of evaluable patients achieved a pathologic complete response following a single treatment cycle. All patients treated with PRV111 avoided planned standard-of-care surgery.
From prnewswire.com
Why it matters
The therapy demonstrated durable responses, with no recurrences observed during a median follow-up of 14 months. The treatment was also reported as well-tolerated, with 85% of treatment-related adverse events being mild.
From prnewswire.com
Who's involved
- PR NewswireDistributor of the corporate announcement
Keep exploring
The entities involved
-
PR Newswire
American distributor of press releases